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OBJECTIVES: Older adults are in an increased risk of respiratory infections includ-
ing community acquired pneumonia (CAP). The former socialistic countries of the
central Europe form a unique region with specific health care and epidemiology
characteristics, and where the local evidence on the underlying epidemiology is
scarce. The objective was to estimate the economic burden of CAP in adults 50
years of age in the Czech Republic (CR), Slovakia (SK), Poland (PL), andHungary (HU)
using data from 2010. METHODS: The incidence of hospitalized CAP stratified by
age groups 50-64, 65-74, 75-84 and 85 was obtained from national surveillance
systems (PL, CR, SK) and insurance records (HU). The estimates of non-hospitalised
CAP incidence was based on retrospective chart reviews (CZ, SK, PL) and the insur-
ance fund records (HU). Direct costs from the payer’s perspective were based on
resource use analyses (CR, SK), DRG lists (PL) and the insurance records (HU).
RESULTS: The incidence of hospitalized CAP per 100,000 person years was: 456.6
(CR), 504.6 (SK), 363.9 (PL), and 845.3 (HU). Compared with adults 50-64 years of age,
the incidence of hospitalised CAPwere 2.3 fold higher in those 65-74, 5.2 fold higher
in 75-84 and 10.8 fold higher in those85,manifesting an exponential trend.While
the majority of CAP among adults 50-64 years of age was treated outpatient, the
proportion of CAP hospitalized increased with increasing age. The total burden of
CAP in adults over 50 was € 12,579,543 (CR); 9,160,774 (SK); 22,409,085 (PL); and
18,298,449 (HU); with hospitalization representing over 90% of the direct costs of
treatment in all 4 countries. Adults 65, who represent 41% of the combined pop-
ulation, account for 73% of the costs. CONCLUSIONS: The incidence and likelihood
of hospitalisation drives the costs of CAP upwards with increasing age in the new
central EU countries.
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OBJECTIVES: Menopause symptoms are a good disease severity proxy for meno-
pausal women, but are not available in claims database. We applied probabilistic
linkage to add symptoms recorded in a registry database to claims data, and com-
pare the healthcare costs among women with various symptoms. METHODS:
Women age 45 or older who used estrogen only hormone therapy (HT) were se-
lected from a large US claims database (41/2005-09/30/2008). Another group who
used estrogen only HT with a menopause diagnosis was selected from the Univer-
sity of Michigan Women’s Registry Database. Logistic regression was used to cal-
culate the propensity score for each patient controlling for osteoporosis, gyneco-
logical disorders/procedures, genital infection, bladder/pelvic floor support
problem, gynecology system cancer, breast condition, gut condition, hormone dis-
order, nerve problem, and other individual comorbidities such as rheumatoid dis-
ease, depression, and blood clotting. Patients with the closest propensity score
from each group were matched, and menopause symptoms for registry patients
were added to the claims database records. After repeating probabilistic linkage
250 times, themean and 95% confidence interval (CI) of healthcare costs during the
follow-up periodwere calculated. RESULTS: 80 patients from each populationwere
matched after probabilistically linking 20,020 claims database patients with 83
registry database patients. The average cost of patients with at least one symptom
was much higher than for patients without symptoms ($13,570 [95% CI: $13,459-
$13,680] vs. $3,391 [95%CI: $3,345-$3,436], p-value0.001). Cost differences were
mainly from inpatient, physician visit, and pharmacy costs. Among patients with
menopause symptoms, those with hot flashes had the highest costs ($10,127), fol-
lowed by memory loss ($1,653), vaginal dryness ($864), reduced libido ($568), and
mood swings ($358). CONCLUSIONS: Women with menopause symptoms incur
higher health care costs than those without This study suggests symptoms are
important determinants of health care expenses and their impact can be assessed
by linking registry and claims databases.
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OBJECTIVES: To evaluate the long-term cost-effectiveness of a fixed-dose combi-
nation (FDC) therapy (0.5mg dutasteride and 0.4mg tamsulosin daily) compared to
0.4mg tamsulosinmonotherapy for the treatment of symptomatic benign prostatic
hyperplasia (BPH).METHODS:We developed a Markov state transition model with
tunnel state and embedded decision tree. The model follows a Quebec cohort of
312,448 male patients aged 50 years, diagnosed with BPH and with symptoms as
defined by an International Prostate Symptom Score 12. This cohort reflects the
population of the 4-year ComBAT trial to evaluate the effect of combination ther-
apy versus either dutasteride or tamsulosin monotherapy on BPH clinical progres-
sion and improvement in BPH symptoms. We conduct this analysis from the per-
spective of the Quebec provincial healthcare system, considering all primary care
and hospital costs. Utility estimates were obtained from published literature. Re-
sults are presented at 10 years and lifetime (up to 25 years) in the form of incre-
mental costs, incremental QALYs and the incremental cost-effectiveness ratio
(ICER). Sensitivity analyses were performed to evaluate the robustness of the
model to variations in the underlying input parameters. RESULTS: Discounted
QALYs per patient at a 10-year time horizon were 6.88 (FDC) and 6.82 (Tamsulosin).
At 10 years the ICER for FDC comparedwith Tamsulosinwas CAD $29,860. The ICER
decreased over time to reach CAD $29,239 over a lifetime horizon. At a willingness
to pay of CAD $50,000 per QALY gained, the probability of FDC being cost-effective
for the symptomatic BPH population was approximately 63%. CONCLUSIONS: FDC
can be cost-effective in treating patients affectedwith enlarged prostatewithmod-
erate or severe symptoms. The sensitivity analyses suggested that variation in
main parameters will not alter the behavior of the comparison between the two
treatments (i.e. FDC is always more effective andmore costly than tamsulosin at a
lifetime time horizon).
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OBJECTIVES:Despite the Ecuadorian policy of vaccination for high risk persons and
adults over 50 years age with 23-valent pneumococcal polysaccharide vaccine
(PPSV23), Streptococcus pneumonia infections continue to be the most common dis-
ease, causing approximately 3,158 deaths every year and raising public health
costs. A 13 valent pneumococcal conjugate vaccine (PCV13) has recently been ap-
proved for use in adults, and is expected to have an additional impact on disease
burden due to covered serotypes. The purpose of this studywas to compare PPSV23
and PCV13 vaccines from an Ecuadorian public perspective. METHODS: A cost-
effectiveness analysis based on a Markov model was developed comparing the
impact and cost-effectiveness of PPSV23 and PCV13 for the prevention of pneumo-
coccal disease in high risk adult population. Time horizon of the model was 35
years, with annual discounting of 5% per annum. The effectiveness measure was
the number of cases avoided and cost differences between the interventions. Re-
source use and costs were obtained from Ministry of Health published data, INEC,
and SIREVA reports. Costs were collected from local healthcare databases.
RESULTS: The model reveals that PCV13 is a cost-saving alternative compared to
PPSV23. Vaccinationwith PCV13 is estimated to prevent an additional 1443 cases of
bacteremia; 162 cases of meningitis; 11,236 cases of inpatient pneumonia; 1,241
cases of outpatient pneumonia and 3413 deaths due disease compared to PPSV23.
Furthermore, vaccination with PCV13 is estimated to save thousands: 25,329 USD
in medical costs, 3,874 USD in non medical costs and 46.027 USD in medical non
medicalvaccination costs. CONCLUSIONS: In Ecuador, a national policy of vacci-
nation with PCV13 is expected to be a cost-saving strategy in the prevention of
pneumococcal disease in high risk patients and adults over 50 years compared to
PPSV23. PPV13 is expected to generate reduction on mortality and morbidity with
lower expected costs.
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OBJECTIVES: To conduct a cost-effectiveness analysis of a universal childhood
hepatitis A vaccination program in Brazilian regions with different hepatitis A
endemicity. METHODS: An age and time-dependent dynamic model was devel-
oped to estimate the incidence of hepatitis A for 24 years. The analysis was run
separately, according to the pattern of regional endemicity, one for Southern 
Southeast (low endemicity) and one for the North  Northeast  Midwest (inter-
mediate endemicity). The decision analysis model compared universal childhood
vaccination with current program of vaccinating high risk individuals. Epidemio-
logic and cost estimates were based on data retrieved from a nationwide seroepi-
demiological survey for viral hepatitis, primary data collection, National Health
Information Systems and literature. The analysis was conducted from the health-
care system and societal perspectives. Costs are expressed in 2008 Brazilian reals.
RESULTS: In this model a universal national immunization program would have a
significant impact on disease epidemiology in all regions, resulting in 64% reduc-
tion in the number of cases of icteric hepatitis, 59% reduction in deaths due to
disease and a 62 % decrease of life years lost, in a national perspective. With a
vaccine price per dose of R$16.89 (US$7.23), vaccination against hepatitis A was a
cost-saving strategy in the low and intermediate endemicity regions and in Brazil
as a whole from healthcare and society perspective. Results weremost sensitive to
icteric hepatitis incidence, ambulatory cases and vaccine costs. CONCLUSIONS:
Universal childhood vaccination program against hepatitis A could be a cost-sav-
ing strategy in all regions of Brazil. These results may be useful for the Brazilian
government for vaccine related decisions and for monitoring population impact if
the vaccine is included in the National Immunization Program.
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